BioCentury | Jan 26, 2018
Clinical News

NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...treatment of metastatic pancreatic cancer and a Phase II trial to treat platinum-resistant ovarian cancer. Morvus Technology Ltd....
...U.K. Product: Acelarin (NUC-1031) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus'...
BioCentury | Jan 19, 2018
Clinical News

NuCana gains on first-line biliary cancer readout

...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...and a Phase II trial to treat platinum-resistant ovarian cancer. Elizabeth S. Eaton Acelarin cisplatin gemcitabine NUC-1031 American Society of Clinical Oncology Morvus Technology Ltd. NuCana...
BioCentury | Jun 13, 2016
Clinical News

Acelarin: Phase Ib data

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
...NUC-1031 , MTL-007 ) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus’...
BioCentury | Jun 8, 2015
Clinical News

Acelarin: Phase I/II final data

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
BioCentury | Apr 14, 2014
Finance

Double vision

...of therapy is very impressive," Healy said. NuCana has rights to the ProTide technology from Morvus Technology Ltd. ...
BioCentury | Apr 11, 2014
Financial News

NuCana raises $57 million in series B

...cell lung cancer (NSCLC). Acelarin is a modified version of gemcitabine using ProTide technology from Morvus Technology Ltd....
BioCentury | Jun 24, 2013
Clinical News

NUC-1031: Phase I data

...Morvus' ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
BioCentury | Nov 30, 2011
Financial News

NuCana raises $10.5M in series A

...and Alida Capital International also participated. NuCana has exclusive, worldwide rights to ProTide technology from Morvus Technology Ltd....
BioCentury | Apr 15, 2010
Distillery Therapeutics

Indication: Infectious disease

...compound optimization. Bayer AG markets Lampit nifurtimox, an antiprotozoal nitrofuran derivative, to treat trypanosome infection. Morvus Technology Ltd.'s...
BioCentury | Jan 7, 2010
Distillery Therapeutics

Indication: Infectious disease

...malaria. Pfizer's macrolide antibiotic Zithromax azithromycin is in Phase III testing to treat pediatric malaria. Morvus Technology Ltd.'s...
Items per page:
1 - 10 of 18
BioCentury | Jan 26, 2018
Clinical News

NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...treatment of metastatic pancreatic cancer and a Phase II trial to treat platinum-resistant ovarian cancer. Morvus Technology Ltd....
...U.K. Product: Acelarin (NUC-1031) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus'...
BioCentury | Jan 19, 2018
Clinical News

NuCana gains on first-line biliary cancer readout

...cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd....
...and a Phase II trial to treat platinum-resistant ovarian cancer. Elizabeth S. Eaton Acelarin cisplatin gemcitabine NUC-1031 American Society of Clinical Oncology Morvus Technology Ltd. NuCana...
BioCentury | Jun 13, 2016
Clinical News

Acelarin: Phase Ib data

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
...NUC-1031 , MTL-007 ) Business: Cancer Molecular target: NA Description: Modified version of gemcitabine using Morvus’...
BioCentury | Jun 8, 2015
Clinical News

Acelarin: Phase I/II final data

...Morvus’ ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
BioCentury | Apr 14, 2014
Finance

Double vision

...of therapy is very impressive," Healy said. NuCana has rights to the ProTide technology from Morvus Technology Ltd. ...
BioCentury | Apr 11, 2014
Financial News

NuCana raises $57 million in series B

...cell lung cancer (NSCLC). Acelarin is a modified version of gemcitabine using ProTide technology from Morvus Technology Ltd....
BioCentury | Jun 24, 2013
Clinical News

NUC-1031: Phase I data

...Morvus' ProTide technology to produce next-generation nucleosides to treat cancer (see BioCentury, Dec. 14, 2009). Morvus Technology Ltd....
BioCentury | Nov 30, 2011
Financial News

NuCana raises $10.5M in series A

...and Alida Capital International also participated. NuCana has exclusive, worldwide rights to ProTide technology from Morvus Technology Ltd....
BioCentury | Apr 15, 2010
Distillery Therapeutics

Indication: Infectious disease

...compound optimization. Bayer AG markets Lampit nifurtimox, an antiprotozoal nitrofuran derivative, to treat trypanosome infection. Morvus Technology Ltd.'s...
BioCentury | Jan 7, 2010
Distillery Therapeutics

Indication: Infectious disease

...malaria. Pfizer's macrolide antibiotic Zithromax azithromycin is in Phase III testing to treat pediatric malaria. Morvus Technology Ltd.'s...
Items per page:
1 - 10 of 18